3rd Cir. Upholds Award of Summary Judgment to Novartis in Aredia/Zometa Action



DOCUMENTS
  • Opinion


PHILADELPHIA — A federal court of appeals has upheld an award of summary judgment to Novartis Pharmaceuticals Corp. in an Aredia/Zometa action, finding the evidence does not show that the drug maker’s allegedly inadequate warnings caused the patient’s osteonecrosis of the jaw.

On Oct. 5, the 3rd Circuit U.S. Court of Appeals found the patient’s prescribing doctors were aware of the risk between the cancer drugs and ONJ, yet would not change their decision to prescribe the drugs.

Aredia and Zometa are intravenously administered bisphosphonates which inhibit bone resorption in patients suffering from hypercalcemia of malignancy, a potentially life-threatening complication …

FIRM NAMES
  • Hollingsworth
  • JonesPassodelis
  • Picadio Sneath Miller & Norton
  • The Levicoff Law Firm





UPCOMING CONFERENCES




HarrisMartin's Masters of Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024

MORE DETAILS